Accredited Investors Inc. Acquires New Position in Colgate-Palmolive Company $CL

Accredited Investors Inc. acquired a new stake in Colgate-Palmolive Company (NYSE:CL) in the 4th quarter, Holdings Channel.com reports. The firm acquired 11,953 shares of the company’s stock, valued at approximately $945,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CL. Brighton Jones LLC raised its position in Colgate-Palmolive by 4.4% during the fourth quarter. Brighton Jones LLC now owns 10,578 shares of the company’s stock worth $962,000 after acquiring an additional 450 shares during the last quarter. Woodline Partners LP raised its position in Colgate-Palmolive by 76.3% during the first quarter. Woodline Partners LP now owns 46,361 shares of the company’s stock worth $4,344,000 after acquiring an additional 20,062 shares during the last quarter. Schnieders Capital Management LLC. raised its position in Colgate-Palmolive by 2.0% during the second quarter. Schnieders Capital Management LLC. now owns 12,494 shares of the company’s stock worth $1,136,000 after acquiring an additional 245 shares during the last quarter. Nebula Research & Development LLC raised its position in Colgate-Palmolive by 165.5% during the second quarter. Nebula Research & Development LLC now owns 10,326 shares of the company’s stock worth $939,000 after acquiring an additional 6,437 shares during the last quarter. Finally, Sei Investments Co. raised its position in Colgate-Palmolive by 21.7% during the second quarter. Sei Investments Co. now owns 657,093 shares of the company’s stock worth $59,732,000 after acquiring an additional 116,968 shares during the last quarter. Institutional investors and hedge funds own 80.41% of the company’s stock.

Trending Headlines about Colgate-Palmolive

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Zacks also highlighted Colgate’s innovation strategy as a support for market share gains, with premium launches, pricing actions and science-based products helping growth in oral care and pet nutrition. Why Colgate’s Innovation Strategy Is Fueling Market Share Gains
• Neutral Sentiment: Analysts lowered near-term and longer-term EPS estimates, but the changes were relatively modest and the new forecasts still point to continued earnings growth over the next few years.
• Negative Sentiment: Zacks Research cut FY2026 EPS to $3.80 from $3.89, FY2027 to $4.01 from $4.15, FY2028 to $4.39 from $4.44, and reduced several quarterly estimates, signaling a slightly less optimistic profit outlook for Colgate-Palmolive. Analyst estimate cuts for Colgate-Palmolive

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on CL. UBS Group lifted their target price on shares of Colgate-Palmolive from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. JPMorgan Chase & Co. lifted their target price on shares of Colgate-Palmolive from $95.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Weiss Ratings upgraded shares of Colgate-Palmolive from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, May 4th. Wells Fargo & Company cut their target price on shares of Colgate-Palmolive from $100.00 to $92.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 8th. Finally, Morgan Stanley restated an “overweight” rating on shares of Colgate-Palmolive in a research report on Monday, May 4th. Twelve analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $95.88.

Colgate-Palmolive Stock Performance

NYSE:CL opened at $88.20 on Friday. The firm has a 50 day simple moving average of $86.30 and a 200-day simple moving average of $84.68. The company has a debt-to-equity ratio of 16.33, a current ratio of 1.02 and a quick ratio of 0.67. The firm has a market cap of $70.76 billion, a PE ratio of 34.32, a P/E/G ratio of 4.57 and a beta of 0.31. Colgate-Palmolive Company has a 1-year low of $74.54 and a 1-year high of $99.33.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, May 1st. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.03. Colgate-Palmolive had a net margin of 10.04% and a return on equity of 386.76%. The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.22 billion. During the same period in the previous year, the firm earned $0.91 earnings per share. Colgate-Palmolive’s revenue was up 8.4% compared to the same quarter last year. On average, equities analysts expect that Colgate-Palmolive Company will post 3.82 EPS for the current year.

Colgate-Palmolive Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Monday, April 20th were issued a $0.53 dividend. The ex-dividend date was Monday, April 20th. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.52. This represents a $2.12 dividend on an annualized basis and a yield of 2.4%. Colgate-Palmolive’s payout ratio is presently 82.49%.

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.